Table 2.

HRs of NRM associated with individual comorbidities in patients receiving low-TCI regimens

Comorbidity	N (%)	Adjusted∗ HR (95% CI)	P
Rheumatologic	40 (2)	0.70 (0.26-1.90)	.489
Moderate pulmonary	275 (17)	0.99 (0.70-1.41)	.954
Active infection	164 (10)	1.06 (0.69-1.63)	.785
Arrythmia	73 (4)	1.15 (0.65-2.02)	.636
Diabetes mellitus	112 (7)	1.17 (0.73-1.88)	.509
Obesity	58 (3)	1.25 (0.66-2.36)	.494
Cerebrovascular	38 (2)	1.28 (0.60-2.74)	.529
Prior malignancy	155 (9)	1.29 (0.85-1.94)	.230
Cardiac disease†	182 (11)	1.32 (0.91-1.90)	.143
Mild/moderate hepatic	90 (5)	1.34 (0.79-2.28)	.273
Severe hepatic	26 (2)	1.38 (0.51-3.74)	.530
Severe pulmonary	183 (11)	1.43 (0.99-2.07)	.058
Composite cardiac‡	263 (16)	1.54 (1.13-2.09)	.006
Psychiatric	75 (5)	1.69 (1.02-2.82)	.043
Valvular disease	38 (2)	2.44 (1.37-4.35)	.002
Peptic ulcer	14 (1)	3.01 (1.11-8.15)	.031
IBD	26 (2)	3.88 (1.90-7.96)	<.001
Renal	20 (1)	5.29 (2.58-10.85)	<.001
HCT-CI§
1-2 points	434 (26)	1.17 (0.83-1.64)	.363
≥3 points	516 (31)	1.70 (1.25-2.30)	.001
Additional covariates‖
KPS <90	523 (29)	1.13 (0.86-1.49)	.365
Age (by decade)		1.71 (1.42-2.07)	<.001

^∗Adjusted for age, KPS, disease risk (disease risk stratification system), donor type, sex mismatch, and donor/recipient cytomegalovirus serostatus.

^†HCT-CI definition.

^‡HCT-CI definition plus valvular disease and arrhythmia.

^§The HCT-CI was not included in the model; HRs adjusted using the same covariates as in ^∗ are shown here for comparison.

^‖Studied as the primary effect in models with the same adjustment covariates.